Nasdaq
$1.72▼ 0.24%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $45.6MShares out 26.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
26- 3d agoAfter-hours26.10.22 05:494Ownership#●●●
TENAX THERAPEUTICS, INC.
Daniel Schneeberger and ADAR1 Capital Management, LLC, both insiders and major shareholders of Tenax Therapeutics, filed a Form 4 report regarding changes in beneficial ownership of securities as of October 19, 2026. Investors can review the filing to assess the specific changes in their equity holdings.…more
$1.72-0.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15After-hours26.10.16 06:28SCHEDULE 13G/AOwnership
TENAX THERAPEUTICS, INC.
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed a Schedule 13G regarding their beneficial ownership of Tenax Therapeutics, Inc. common stock. This filing is made in accordance with a joint filing agreement dated October 14, 2026.…more
$1.72-0.24%vs prev closeView filingShare - 10.13Pre-market26.10.13 19:05SCHEDULE 13G/AOwnership
TENAX THERAPEUTICS, INC.
Sphera Funds Management Ltd. has filed a SCHEDULE 13G/A amendment regarding its beneficial ownership in Tenax Therapeutics, Inc. The reporting entity has officially updated its stake information with the SEC.…more
$1.72-0.24%vs prev closeView filingShare
25 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.8After-hours26.10.09 05:22Bullish#●●●#●●●
Tenax Therapeutics Pauses LEVEL-2 Trial Enrollment for TNX-103
Tenax Therapeutics has temporarily paused enrollment in its LEVEL-2 clinical trial for TNX-103 to amend study criteria. The company is currently seeking a meeting with the FDA to discuss these adjustments.…more
$1.72-0.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.1Pre-market26.09.01 20:00
●●●●●●●● ●●●●● ●●●●●●
Tenax Therapeutics announced that its CEO will present at the 2026 Cantor Global Healthcare Conference on September 9. This event serves as an opportunity to update investors on clinical progress, but does not represent a material financial catalyst.…more
$1.72-0.24%vs prev close - 8.31Overnight26.08.31 16:37
●●●●●●●● ●●●●● ●●●●●●
Tenax Therapeutics presented additional Phase 3 data for TNX-103 at the ESC Congress, demonstrating favorable treatment effects in specific patient groups. The results showed consistent improvements in cardiac stress and pulmonary pressure markers, though further clinical validation remains necessary.…more
$1.72-0.24%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report